Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease

Biochemical and Biophysical Research Communications

Volumn 462, Issue 4, 2015, Pages 283-287

  Kim, Manbok ^a,b   Rahman, Masmudur M ^a   Cogle, Christopher R ^a   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Dankook University   (South Korea)

Author keywords

Anti cancer therapy; EBV lymphoma; Myxoma virus; Oncolytic virus; Viral purging

Indexed keywords

ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL VIABILITY; EPSTEIN BARR VIRUS INFECTION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MORBIDITY; MOUSE; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; TUMOR VOLUME; XENOTRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; COMPLICATION; DISEASE MODEL; EPSTEIN BARR VIRUS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; TRANSPLANTATION; VIROLOGY; XENOGRAFT;

ANIMALIA; HUMAN HERPESVIRUS 4; MURINAE; MYXOMA VIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; HERPESVIRUS 4, HUMAN; HETEROGRAFTS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MICE; ONCOLYTIC VIROTHERAPY; TRANSPLANTATION;

EID: 84930754662     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.03.146     Document Type: Article

References (25)

1. K.A. Parato, D. Senger, P.A. Forsyth, and J.C. Bell Recent progress in the battle between oncolytic viruses and tumours Nat. Rev. Cancer 5 2005 965 976
2. S.J. Russell, K.W. Peng, and J.C. Bell Oncolytic virotherapy Nat. Biotechnol. 10 2012 658 670
3. J.E. Strong, M.C. Coffey, D. Tang, P. Sabinin, and P.W. Lee The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus EMBO J. 17 1998 3351 3362
4. G. Wang, J.W. Barrett, M. Stanford, S.J. Werden, and J.B. Johnston Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor Proc. Natl. Acad. Sci. U. S. A. 103 2006 4640 4645
5. M. Kim, C.T. Williamson, J. Prudhomme, and D.G. Bebb The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status Oncogene 29 2010 3990 3996
6. M. Kim, G.J. Madlambayan, and M.M. Rahman Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells Leukemia 23 2009 2313 2317
7. G. McFadden Poxvirus tropism Nat. Rev. Microbiol. 3 2005 201 213
8. M.M. Stanford, S.J. Werden, and G. McFadden Myxoma virus in the European rabbit: interactions between the virus and its susceptible host Vet. Res. 38 2007 299 318
9. X. Lun, W. Yang, T. Alain, and Z.Q. Shi Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas Cancer Res. 65 2005 9982 9990
10. A.B. Rickinson, and E. Kieff Epstein-Barr virus D.M. Knipe, P.M. Howley, Fields Virology 5 ed 2007 Wolters Kluwer/Lippincott Williams and Wilkins Philadelphia 2655 2700
11. S. Gottschalk, C.M. Rooney, and H.E. Heslop Post-transplant lymphoproliferative disorders Annu Rev. Med. 56 2005 29 44
12. P.L. Dahia, R.C. Aguiar, and J. Alberta PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies Hum. Mol. Genet. 8 1999 185 193
13. G.C. Fillmore, Q. Wang, and M.J. Carey Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas Leuk. Lymphoma 46 2005 1765 1773
14. L. Young, C. Alfieri, K. Hennessy, and H. Evans Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease N. Engl. J. Med. 321 1989 1080 1085
15. T.E. Starzl, M.A. Nalesnik, K.A. Porter, and M. Ho Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 1984 583 587
16. C. Caldas, and R. Ambinder Epstein-Barr virus and bone marrow transplantation Curr. Opin. Oncol. 7 1995 102 106
17. A.B. Rickinson, and D.J. Moss Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection Annu Rev. Immunol. 15 1997 405 431
18. K.G. Lucas, T.N. Small, G. Heller, B. Dupont, and R.J. O'Reilly The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation Blood 87 1996 2594 2603
19. H.E. Heslop, and C.M. Rooney Adoptive cellular immunotherapy for EBV lymphoproliferative disease Immunol. Rev. 157 1997 217 222
20. R.J. O'Reilly, T.N. Small, and E. Papadopoulos Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts Immunol. Rev. 157 1997 195 216
21. L.J. Swinnen Treatment of organ transplant-related lymphoma Hematol. Oncol. Clin. North Am. 11 1997 963 973
22. I. Avital, A.L. Moreira, D.S. Klimstra, and M. Leversha Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation Stem Cells 25 2007 2903 2909
23. C.W. Dawson, G. Tramountanis, A.G. Eliopoulos, and L.S. Young Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling J. Biol. Chem. 278 2003 3694 3704
24. R. Swart, I.K. Ruf, J. Sample, and R. Longnecker Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway J. Virol. 74 2000 10838 10845
25. M. Sugimoto, H. Tahara, T. Ide, and Y. Furuichi Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus Cancer Res. 64 2004 3361 3364